Report Detail
Global Pulmonary Drugs Market Insights, Forecast to 2025
- RnM2700498 |
- 12 June, 2019 |
- Global |
- 119 Pages |
- QYResearch |
- Pharma & Healthcare
The pulmonary drugs are used for treating the conditions affecting lungs. The pulmonary drugs are used from treating minor illnesses such as the common cold to cure long-term disorders such asthma. These agents are available in different forms such as oral tablets, oral liquids, and injections or inhalations. Inhalations deliver the medicine directly to the lungs, which can act directly on the lung tissues, minimizing systemic side effects.
The major factors driving growth of the pulmonary drugs market include increasing incidence of chronic respiratory diseases, tobacco smoking, and government and non-government initiatives.
The global Pulmonary Drugs market is valued at 30400 million US$ in 2018 and will reach 56600 million US$ by the end of 2025, growing at a CAGR of 8.1% during 2019-2025. The objectives of this study are to define, segment, and project the size of the Pulmonary Drugs market based on company, product type, end user and key regions.
This report studies the global market size of Pulmonary Drugs in key regions like North America, Europe, Asia Pacific, Central & South America and Middle East & Africa, focuses on the consumption of Pulmonary Drugs in these regions.
This research report categorizes the global Pulmonary Drugs market by top players/brands, region, type and end user. This report also studies the global Pulmonary Drugs market status, competition landscape, market share, growth rate, future trends, market drivers, opportunities and challenges, sales channels and distributors.
The following manufacturers are covered in this report, with sales, revenue, market share for each company:
Sanofi SA
Meda Pharmaceuticals
Circassia Pharmaceuticals Plc.
AstraZeneca Plc.
GlaxoSmithKline Plc.
Mallinckrodt Pharmaceuticals Plc.
Cheisi Farmaceutici S.p.A
Zambon Company S.p.A
Alaxia SAS
Merck Sharp & Dohme Limited
Market size by Product
Inhaled Corticosteroids
Long Acting Beta-2 Agonists
Antihistamines
Vasodilators
Others
Market size by End User
Asthma & COPD
Allergic Rhinitis
Pulmonary Arterial Hypertension
Cystic Fibrosis
Others
Market size by Region
North America
United States
Canada
Mexico
Asia-Pacific
China
India
Japan
South Korea
Australia
Indonesia
Singapore
Malaysia
Philippines
Thailand
Vietnam
Europe
Germany
France
UK
Italy
Spain
Russia
Central & South America
Brazil
Rest of Central & South America
Middle East & Africa
GCC Countries
Turkey
Egypt
South Africa
The study objectives of this report are:
To study and analyze the global Pulmonary Drugs market size (value & volume) by company, key regions, products and end user, breakdown data from 2014 to 2018, and forecast to 2025.
To understand the structure of Pulmonary Drugs market by identifying its various subsegments.
To share detailed information about the key factors influencing the growth of the market (growth potential, opportunities, drivers, industry-specific challenges and risks).
Focuses on the key global Pulmonary Drugs companies, to define, describe and analyze the sales volume, value, market share, market competition landscape and recent development.
To project the value and sales volume of Pulmonary Drugs submarkets, with respect to key regions.
To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
In this study, the years considered to estimate the market size of Pulmonary Drugs are as follows:
History Year: 2014-2018
Base Year: 2018
Estimated Year: 2019
Forecast Year 2019 to 2025
This report includes the estimation of market size for value (million US$) and volume (K Units). Both top-down and bottom-up approaches have been used to estimate and validate the market size of Pulmonary Drugs market, to estimate the size of various other dependent submarkets in the overall market. Key players in the market have been identified through secondary research, and their market shares have been determined through primary and secondary research. All percentage shares, splits, and breakdowns have been determined using secondary sources and verified primary sources.
For the data information by region, company, type and application, 2018 is considered as the base year. Whenever data information was unavailable for the base year, the prior year has been considered.
Table of Contents
1 Study Coverage
- 1.1 Pulmonary Drugs Product
- 1.2 Market Segments
- 1.3 Key Manufacturers Covered
- 1.4 Market by Type
- 1.4.1 Global Pulmonary Drugs Market Size Growth Rate by Product
- 1.4.2 Inhaled Corticosteroids
- 1.4.3 Long Acting Beta-2 Agonists
- 1.4.4 Antihistamines
- 1.4.5 Vasodilators
- 1.4.6 Others
- 1.5 Market by End User
- 1.5.1 Global Pulmonary Drugs Market Size Growth Rate by End User
- 1.5.2 Asthma & COPD
- 1.5.3 Allergic Rhinitis
- 1.5.4 Pulmonary Arterial Hypertension
- 1.5.5 Cystic Fibrosis
- 1.5.6 Others
- 1.6 Study Objectives
- 1.7 Years Considered
2 Executive Summary
- 2.1 Global Pulmonary Drugs Market Size
- 2.1.1 Global Pulmonary Drugs Revenue 2014-2025
- 2.1.2 Global Pulmonary Drugs Sales 2014-2025
- 2.2 Pulmonary Drugs Growth Rate by Regions
- 2.2.1 Global Pulmonary Drugs Sales by Regions
- 2.2.2 Global Pulmonary Drugs Revenue by Regions
3 Breakdown Data by Manufacturers
- 3.1 Pulmonary Drugs Sales by Manufacturers
- 3.1.1 Pulmonary Drugs Sales by Manufacturers
- 3.1.2 Pulmonary Drugs Sales Market Share by Manufacturers
- 3.1.3 Global Pulmonary Drugs Market Concentration Ratio (CR5 and HHI)
- 3.2 Pulmonary Drugs Revenue by Manufacturers
- 3.2.1 Pulmonary Drugs Revenue by Manufacturers (2014-2019)
- 3.2.2 Pulmonary Drugs Revenue Share by Manufacturers (2014-2019)
- 3.3 Pulmonary Drugs Price by Manufacturers
- 3.4 Pulmonary Drugs Manufacturing Base Distribution, Product Types
- 3.4.1 Pulmonary Drugs Manufacturers Manufacturing Base Distribution, Headquarters
- 3.4.2 Manufacturers Pulmonary Drugs Product Type
- 3.4.3 Date of International Manufacturers Enter into Pulmonary Drugs Market
- 3.5 Manufacturers Mergers & Acquisitions, Expansion Plans
4 Breakdown Data by Product
- 4.1 Global Pulmonary Drugs Sales by Product
- 4.2 Global Pulmonary Drugs Revenue by Product
- 4.3 Pulmonary Drugs Price by Product
5 Breakdown Data by End User
- 5.1 Overview
- 5.2 Global Pulmonary Drugs Breakdown Data by End User
6 North America
- 6.1 North America Pulmonary Drugs by Countries
- 6.1.1 North America Pulmonary Drugs Sales by Countries
- 6.1.2 North America Pulmonary Drugs Revenue by Countries
- 6.1.3 United States
- 6.1.4 Canada
- 6.1.5 Mexico
- 6.2 North America Pulmonary Drugs by Product
- 6.3 North America Pulmonary Drugs by End User
7 Europe
- 7.1 Europe Pulmonary Drugs by Countries
- 7.1.1 Europe Pulmonary Drugs Sales by Countries
- 7.1.2 Europe Pulmonary Drugs Revenue by Countries
- 7.1.3 Germany
- 7.1.4 France
- 7.1.5 UK
- 7.1.6 Italy
- 7.1.7 Russia
- 7.2 Europe Pulmonary Drugs by Product
- 7.3 Europe Pulmonary Drugs by End User
8 Asia Pacific
- 8.1 Asia Pacific Pulmonary Drugs by Countries
- 8.1.1 Asia Pacific Pulmonary Drugs Sales by Countries
- 8.1.2 Asia Pacific Pulmonary Drugs Revenue by Countries
- 8.1.3 China
- 8.1.4 Japan
- 8.1.5 Korea
- 8.1.6 India
- 8.1.7 Australia
- 8.1.8 Indonesia
- 8.1.9 Malaysia
- 8.1.10 Philippines
- 8.1.11 Thailand
- 8.1.12 Vietnam
- 8.1.13 Singapore
- 8.2 Asia Pacific Pulmonary Drugs by Product
- 8.3 Asia Pacific Pulmonary Drugs by End User
9 Central & South America
- 9.1 Central & South America Pulmonary Drugs by Countries
- 9.1.1 Central & South America Pulmonary Drugs Sales by Countries
- 9.1.2 Central & South America Pulmonary Drugs Revenue by Countries
- 9.1.3 Brazil
- 9.2 Central & South America Pulmonary Drugs by Product
- 9.3 Central & South America Pulmonary Drugs by End User
10 Middle East and Africa
- 10.1 Middle East and Africa Pulmonary Drugs by Countries
- 10.1.1 Middle East and Africa Pulmonary Drugs Sales by Countries
- 10.1.2 Middle East and Africa Pulmonary Drugs Revenue by Countries
- 10.1.3 GCC Countries
- 10.1.4 Turkey
- 10.1.5 Egypt
- 10.1.6 South Africa
- 10.2 Middle East and Africa Pulmonary Drugs by Product
- 10.3 Middle East and Africa Pulmonary Drugs by End User
11 Company Profiles
- 11.1 Sanofi SA
- 11.1.1 Sanofi SA Company Details
- 11.1.2 Company Business Overview
- 11.1.3 Sanofi SA Pulmonary Drugs Sales, Revenue and Gross Margin (2014-2019)
- 11.1.4 Sanofi SA Pulmonary Drugs Products Offered
- 11.1.5 Sanofi SA Recent Development
- 11.2 Meda Pharmaceuticals
- 11.2.1 Meda Pharmaceuticals Company Details
- 11.2.2 Company Business Overview
- 11.2.3 Meda Pharmaceuticals Pulmonary Drugs Sales, Revenue and Gross Margin (2014-2019)
- 11.2.4 Meda Pharmaceuticals Pulmonary Drugs Products Offered
- 11.2.5 Meda Pharmaceuticals Recent Development
- 11.3 Circassia Pharmaceuticals Plc.
- 11.3.1 Circassia Pharmaceuticals Plc. Company Details
- 11.3.2 Company Business Overview
- 11.3.3 Circassia Pharmaceuticals Plc. Pulmonary Drugs Sales, Revenue and Gross Margin (2014-2019)
- 11.3.4 Circassia Pharmaceuticals Plc. Pulmonary Drugs Products Offered
- 11.3.5 Circassia Pharmaceuticals Plc. Recent Development
- 11.4 AstraZeneca Plc.
- 11.4.1 AstraZeneca Plc. Company Details
- 11.4.2 Company Business Overview
- 11.4.3 AstraZeneca Plc. Pulmonary Drugs Sales, Revenue and Gross Margin (2014-2019)
- 11.4.4 AstraZeneca Plc. Pulmonary Drugs Products Offered
- 11.4.5 AstraZeneca Plc. Recent Development
- 11.5 GlaxoSmithKline Plc.
- 11.5.1 GlaxoSmithKline Plc. Company Details
- 11.5.2 Company Business Overview
- 11.5.3 GlaxoSmithKline Plc. Pulmonary Drugs Sales, Revenue and Gross Margin (2014-2019)
- 11.5.4 GlaxoSmithKline Plc. Pulmonary Drugs Products Offered
- 11.5.5 GlaxoSmithKline Plc. Recent Development
- 11.6 Mallinckrodt Pharmaceuticals Plc.
- 11.6.1 Mallinckrodt Pharmaceuticals Plc. Company Details
- 11.6.2 Company Business Overview
- 11.6.3 Mallinckrodt Pharmaceuticals Plc. Pulmonary Drugs Sales, Revenue and Gross Margin (2014-2019)
- 11.6.4 Mallinckrodt Pharmaceuticals Plc. Pulmonary Drugs Products Offered
- 11.6.5 Mallinckrodt Pharmaceuticals Plc. Recent Development
- 11.7 Cheisi Farmaceutici S.p.A
- 11.7.1 Cheisi Farmaceutici S.p.A Company Details
- 11.7.2 Company Business Overview
- 11.7.3 Cheisi Farmaceutici S.p.A Pulmonary Drugs Sales, Revenue and Gross Margin (2014-2019)
- 11.7.4 Cheisi Farmaceutici S.p.A Pulmonary Drugs Products Offered
- 11.7.5 Cheisi Farmaceutici S.p.A Recent Development
- 11.8 Zambon Company S.p.A
- 11.8.1 Zambon Company S.p.A Company Details
- 11.8.2 Company Business Overview
- 11.8.3 Zambon Company S.p.A Pulmonary Drugs Sales, Revenue and Gross Margin (2014-2019)
- 11.8.4 Zambon Company S.p.A Pulmonary Drugs Products Offered
- 11.8.5 Zambon Company S.p.A Recent Development
- 11.9 Alaxia SAS
- 11.9.1 Alaxia SAS Company Details
- 11.9.2 Company Business Overview
- 11.9.3 Alaxia SAS Pulmonary Drugs Sales, Revenue and Gross Margin (2014-2019)
- 11.9.4 Alaxia SAS Pulmonary Drugs Products Offered
- 11.9.5 Alaxia SAS Recent Development
- 11.10 Merck Sharp & Dohme Limited
- 11.10.1 Merck Sharp & Dohme Limited Company Details
- 11.10.2 Company Business Overview
- 11.10.3 Merck Sharp & Dohme Limited Pulmonary Drugs Sales, Revenue and Gross Margin (2014-2019)
- 11.10.4 Merck Sharp & Dohme Limited Pulmonary Drugs Products Offered
- 11.10.5 Merck Sharp & Dohme Limited Recent Development
12 Future Forecast
- 12.1 Pulmonary Drugs Market Forecast by Regions
- 12.1.1 Global Pulmonary Drugs Sales Forecast by Regions 2019-2025
- 12.1.2 Global Pulmonary Drugs Revenue Forecast by Regions 2019-2025
- 12.2 Pulmonary Drugs Market Forecast by Product
- 12.2.1 Global Pulmonary Drugs Sales Forecast by Product 2019-2025
- 12.2.2 Global Pulmonary Drugs Revenue Forecast by Product 2019-2025
- 12.3 Pulmonary Drugs Market Forecast by End User
- 12.4 North America Pulmonary Drugs Forecast
- 12.5 Europe Pulmonary Drugs Forecast
- 12.6 Asia Pacific Pulmonary Drugs Forecast
- 12.7 Central & South America Pulmonary Drugs Forecast
- 12.8 Middle East and Africa Pulmonary Drugs Forecast
13 Market Opportunities, Challenges, Risks and Influences Factors Analysis
- 13.1 Market Opportunities and Drivers
- 13.2 Market Challenges
- 13.3 Market Risks/Restraints
- 13.4 Macroscopic Indicators
14 Value Chain and Sales Channels Analysis
- 14.1 Value Chain Analysis
- 14.2 Pulmonary Drugs Customers
- 14.3 Sales Channels Analysis
- 14.3.1 Sales Channels
- 14.3.2 Distributors
15 Research Findings and Conclusion
16 Appendix
- 16.1 Research Methodology
- 16.1.1 Methodology/Research Approach
- 16.1.2 Data Source
- 16.2 Author Details
Summary:
Get latest Market Research Reports on Pulmonary Drugs . Industry analysis & Market Report on Pulmonary Drugs is a syndicated market report, published as Global Pulmonary Drugs Market Insights, Forecast to 2025. It is complete Research Study and Industry Analysis of Pulmonary Drugs market, to understand, Market Demand, Growth, trends analysis and Factor Influencing market.
REPORT YOU MIGHT BE INTERESTED
Related Reports
Reason to Buy
Reports and Markets
Contact Us
+1-352-353-0818 (US)Newsletter
KEEP UP TO DATE ON ALL THE LATEST REPORTS
